UIH(SH:688271) Zheng Quan Shi Bao Wang·2025-09-03 07:06Core Insights - The company reported a revenue of 6.016 billion yuan for the first half of 2025, representing a year-on-year growth of 12.79%, and a net profit of 966 million yuan, up 21.01% year-on-year [1][2] Group 1: Financial Performance - The company achieved a revenue of 60.16 billion yuan in the first half of 2025, marking a 12.79% increase compared to the previous year [1] - The net profit attributable to the parent company was 9.66 billion yuan, reflecting a 21.01% year-on-year growth [1] Group 2: ESG Initiatives - The company established a carbon management task force to enhance environmental governance and carbon emission management, aiming for a 50% reduction in carbon emission intensity by 2035 based on 2023 levels [1] - The company participated in the CDP questionnaire for the first time, achieving a management-level rating of B, indicating strong governance in environmental information management [1] - The uCT780X CT device received ISO 14067 product carbon footprint verification, becoming the first large medical equipment in China to achieve this certification, showcasing the company's commitment to "green manufacturing" [1] Group 3: Supply Chain and Compliance - The company strengthened compliance and supply chain governance, successfully onboarding 12 new suppliers who passed evaluations, ensuring a stable and controllable supply chain [2] - All 68 suppliers audited in the annual plan met the company's standards in technology, delivery, quality management, and social environmental responsibility [2] Group 4: Human Resources and Incentives - The company launched a restricted stock incentive plan in June 2025, granting 4.47 million shares at 94.92 yuan per share to 1,368 employees, aligning the interests of shareholders, the company, and key employees [2] Group 5: ESG Ratings - The company's MSCI ESG rating improved to A, and it ranked among the top 15 in the global medical device industry in the S&P Global Sustainability Assessment [2]